2Mercolini L,Grillo M,Bartoletti C,Boncompagni G,Raggi M A. Simultaneous analysis of classical neurolep-tics,atypical antipsychotics and their metabolites in hu-man plasma [ J]. Anal Bioanal Chem,2007,388 :235-243.
3Stanworth D,Hunt N C,Flanagan R J. Clozapine:adangerous drug in a clozapine-naive subject [J].Foren-sic Sci Int,2012,214(1-3):e23-e25.
4Grinevich V P,Papke R L,Lippiello P M,Bencherif M.A typical antipsychotics as noncompetitive inhibitors ofalpha4beta2 and alpha7 neuronal nicotinic receptors[J].Neuropharmacology,2009 ,57 :183-191.
5Couchman L,Morgan P E,Spencer E P,Johnston A,Flanagan R J. Plasma clozapine and norclozapine in pa-tients prescribed different brands of clozapine (Cloz-aril,Denzapine? and Zaponex)[J].Ther Drug Monit,2010,32:624-627.
6Gonzalez-Esquivel D F?Castro N,Ramirez-Bermudez J,Custodio V,Rojas-Tome S,Castro-Roman R,et al.Plasma levels of clozapine and norclozapine in Mexicanschizophrenia patients [ J]. Arzneimittelforschung,2011,61:335-339.
8Zhou S F,Yang L P,Zhou Z W,Liu Y H,Chan E. In-sights into the substrate specificity,inhibitors,regula-tion,and polymorphisms and the clinical impact of hu-man cytochrome P450 1 A2[J].AAPS J,2009 ,11 :481-494.
9Castberg I,Skogvoll E,Spigset O. Quetiapine and druginteractions:evidence from a routine therapeutic drugmonitoring service [J].J Clin Psychiatry,2007,68:1540-1545.
10Rajkumar A P,Poonkuzhali B,Kuruvilla A,Jacob M,Jacob K S. Clinical predictors of serum clozapine levelsin patients with treatment-resistant schizophrenia [J].Int Clin Psychopharmacol,2013 ,28 :50-56.
